Prediction for oxaliplatin‐induced liver injury using patient‐derived liver organoids
Cancer Medicine · 2024-02 · 13 (3)
DOI: 10.1002/cam4.7042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 24.02.2024. Verfasst von Kumiko Tatsumi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Drug Discovery and Development, Research Center, Osaka International Cancer Institute, Osaka, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Chemical and Drug Induced Liver Injury, Chronic, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Osaka International Cancer Institute, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Background
Liver injury associated with oxaliplatin (L‐OHP)‐based chemotherapy can significantly impact the treatment outcomes of patients with colorectal cancer liver metastases, especially when combined with surgery. To date, no definitive biomarker that can predict the risk of liver injury has been identified. This study aimed to investigate whether organoids can be used as tools to predict the risk of liver injury.
Methods
We examined the relationship between the clinical signs of L‐OHP‐induced liver injury and the responses of patient‐derived liver organoids in vitro . Organoids were established from noncancerous liver tissues obtained from 10 patients who underwent L‐OHP‐based chemotherapy and hepatectomy for colorectal cancer.
Results
Organoids cultured in a galactose differentiation medium, which can activate the mitochondria of organoids, showed sensitivity to L‐OHP cytotoxicity, which was significantly related to clinical liver toxicity induced by L‐OHP treatment. Organoids from patients who presented with a high‐grade liver injury to the L‐OHP regimen showed an obvious increase in mitochondrial superoxide levels and a significant decrease in mitochondrial membrane potential with L‐OHP exposure. L‐OHP‐induced mitochondrial oxidative stress was not observed in the organoids from patients with low‐grade liver injury.
Conclusions
These results suggested that L‐OHP‐induced liver injury may be caused by mitochondrial oxidative damage. Furthermore, patient‐derived liver organoids may be used to assess susceptibility to L‐OHP‐induced liver injury in individual patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Drug Discovery and Development, Research Center, Osaka International Cancer Institute, Osaka, Japan.
- Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
- Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan.
- Project Division of Cancer Biomolecular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Kumiko Tatsumi, Takashi Akazawa, Yu Mizote, Shintaro Okumura
Förderung
- Osaka International Cancer Institute
- Japan Agency for Medical Research and Development
Zitieren
APA
Tatsumi, K., Wada, H., Hasegawa, S., Asukai, K., Nagata, S., Ekawa, T., Akazawa, T., Mizote, Y., Okumura, S., Okamura, R., Ohue, M., Obama, K., & Tahara, H. (2024). Prediction for oxaliplatin‐induced liver injury using patient‐derived liver organoids. Cancer Medicine, 13(3). https://doi.org/10.1002/cam4.7042
Vancouver
Tatsumi K, Wada H, Hasegawa S, Asukai K, Nagata S, Ekawa T, et al. Prediction for oxaliplatin‐induced liver injury using patient‐derived liver organoids. Cancer Medicine. 2024;13(3). doi:10.1002/cam4.7042
BibTeX
@article{Tatsumi2024,
author = {Tatsumi, Kumiko and Wada, Hiroshi and Hasegawa, Shinichiro and Asukai, Kei and Nagata, Shigenori and Ekawa, Tomoya and Akazawa, Takashi and Mizote, Yu and Okumura, Shintaro and Okamura, Ryosuke and Ohue, Masayuki and Obama, Kazutaka and Tahara, Hideaki},
title = {Prediction for oxaliplatin‐induced liver injury using patient‐derived liver organoids},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {3},
doi = {10.1002/cam4.7042}
}
EUVIMED